Your browser doesn't support javascript.
loading
Mechanisms of acute hypercalcemia in pediatric patients following the interruption of Denosumab.
Deodati, A; Fintini, D; Levtchenko, E; Rossi, M; Ubertini, G; Segers, H; Battafarano, G; Cappa, M; Del Fattore, A.
Afiliación
  • Deodati A; Endocrinology Unit, University Pediatric Clinical Department, Bambino Gesù Children's Hospital, IRCCS, 00146, Rome, Italy.
  • Fintini D; Endocrinology Unit, University Pediatric Clinical Department, Bambino Gesù Children's Hospital, IRCCS, 00146, Rome, Italy.
  • Levtchenko E; Department of Pediatrics, University Hospitals Leuven, 3000, Leuven, Belgium.
  • Rossi M; Bone Physiopathology Research Unit, Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCCS, Viale San Paolo 15, 00146, Rome, Italy.
  • Ubertini G; Endocrinology Unit, University Pediatric Clinical Department, Bambino Gesù Children's Hospital, IRCCS, 00146, Rome, Italy.
  • Segers H; Department of Pediatrics, University Hospitals Leuven, 3000, Leuven, Belgium.
  • Battafarano G; Bone Physiopathology Research Unit, Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCCS, Viale San Paolo 15, 00146, Rome, Italy.
  • Cappa M; Endocrinology Unit, University Pediatric Clinical Department, Bambino Gesù Children's Hospital, IRCCS, 00146, Rome, Italy.
  • Del Fattore A; Bone Physiopathology Research Unit, Genetics and Rare Diseases Research Division, Bambino Gesù Children's Hospital, IRCCS, Viale San Paolo 15, 00146, Rome, Italy. andrea.delfattore@opbg.net.
J Endocrinol Invest ; 45(1): 159-166, 2022 Jan.
Article en En | MEDLINE | ID: mdl-34216372

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Privación de Tratamiento / Denosumab / Hipercalcemia Tipo de estudio: Observational_studies Límite: Adolescent / Child / Humans / Male País/Región como asunto: Europa Idioma: En Revista: J Endocrinol Invest Año: 2022 Tipo del documento: Article País de afiliación: Italia

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Privación de Tratamiento / Denosumab / Hipercalcemia Tipo de estudio: Observational_studies Límite: Adolescent / Child / Humans / Male País/Región como asunto: Europa Idioma: En Revista: J Endocrinol Invest Año: 2022 Tipo del documento: Article País de afiliación: Italia